Sector News

Biogen poaches Pfizer vet Villalobos for biotherapeutics lead

August 2, 2017
Life sciences

Biogen has taken Anabella Villalobos, Ph.D., away from Pfizer and placed her as its new SVP of biotherapeutic and medicinal sciences.

With her new role and team, Villalobos will lead Biogen’s BTMS organization in the delivery of “high-quality, differentiated molecules” to the clinic, according to a statement. She will report to Michael Ehlers, M.D., Ph.D., the Big Biotech’s head of R&D.

“We are excited to have Anabella Villalobos join us at Biogen,” said Ehlers. “Anabella is a world-class drug hunter, a proven leader in medicinal sciences, and a champion of scientific innovation. Her experience in neuroscience and passion for drug discovery will help us create and advance the next generation of breakthrough medicines.”

Villalobos comes to Biogen from Pfizer worldwide research and development, most recently being the Big Pharma’s VP and head of medicinal synthesis technologies.

She’s been in the industry for 25 years, spending much of her career working in areas of neuroscience and medicinal chemistry, and on clinical candidates for Alzheimer’s disease, Parkinson’s disease, schizophrenia and pain.

CNS is becoming the biggest focus of Biogen’s pipeline, with much hope being rested on its Alzheimer’s candidate aducanumab, which has seen both positives and negatives in recent read-outs, and will need to buck the terrible trend of Alzheimer’s R&D in recent years, which has seen a near 99% failure rate.

In its financials last week, it also announced that it “intends to remain focused on neuroscience and adjacencies,” which could include deals in these areas. The specific aim is to bolster its pipeline, while also streamlining some ops to allocate more to R&D, with $400 million on the table for this operation.

“Biogen has been an absolute pacesetter in developing breakthrough neurology medicines in the form of biologics, small molecules and new anti-sense oligonucleotide therapies for patients.” said Villalobos.

“I am honored to lead Biotherapeutic & Medicinal Sciences, and I look forward to accelerating our neuroscience discovery to find new approaches for the most challenging conditions of the brain.”

By Ben Adams

Source: FierceBiotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”